Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of NS-304 (selexipag) in pulmonary arterial hypertension
jRCT2080221493Phase 2
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy, Heritable Pulmonary Arterial Hypertension (HPAH) and 1 more, sponsored by Nippon Shinyaku.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyHeritable Pulmonary Arterial Hypertension (HPAH)Pulmonary Arterial Hypertension (PAH)
Beyond the preview
Go deeper on jRCT2080221493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221493.